Does SelectHealth Cover Adderall?

What Is SelectHealth and How Does Its Drug Coverage Work?

SelectHealth is a Utah-based health insurer affiliated with Intermountain Health, offering individual, family, employer-sponsored, and Medicare Advantage plans primarily across Utah, Idaho, and Nevada. Each plan carries its own formulary, a tiered list of covered drugs, published annually in the Evidence of Coverage (EOC) or Summary of Benefits and Coverage document.

Prescription drug benefits at SelectHealth follow a standard tiered structure. Tier 1 covers preferred generics at the lowest cost-share. Tier 2 covers non-preferred generics and some preferred brands. Tier 3 and Tier 4 cover non-preferred brands and specialty drugs at the highest cost-share. Where a drug lands depends on the plan year, your specific plan (SelectHealth Advantage, SelectHealth Care, SelectHealth Share, etc.), and whether you are on a commercial or Medicare Advantage contract.

The FDA-approved prescribing information for amphetamine mixed salts (Adderall, generic equivalents) classifies this compound as a Schedule II controlled substance indicated for attention deficit hyperactivity disorder and narcolepsy [1]. That Schedule II status influences how insurers handle coverage. Controlled substance policies at many carriers, including SelectHealth, may impose additional steps such as quantity limits (typically a 30-day supply per fill), mandatory electronic prescribing, and prior authorization even when the drug appears on the formulary.

Formularies change on January 1 of each plan year, so coverage that applied in 2024 may differ in 2025. The SelectHealth Drug List (formulary) is publicly searchable at selecthealth.org, and members can verify current tier placement and any utilization management requirements before filling a prescription.

Does SelectHealth Actually Cover Adderall?

In most SelectHealth commercial plans, brand-name Adderall (mixed amphetamine salts IR) appears on Tier 3 or Tier 4, meaning coverage exists but cost-share is substantial without prior authorization approval or step therapy completion. Generic amphetamine salts immediate-release and extended-release formulations typically appear on Tier 1 or Tier 2.

SelectHealth Medicare Advantage plans follow CMS Part D formulary rules. Under the CMS 2025 Part D final rule, all Schedule II stimulants require prior authorization at the plan level [2]. That means any Medicare Advantage member seeking Adderall or its generic will need a prior authorization on file regardless of tier.

The practical answer is: SelectHealth does cover amphetamine salts in some form on most plans, but brand-name Adderall without prior authorization is rarely paid at a preferred rate. Members who receive a generic amphetamine salt prescription and fill it at an in-network pharmacy will generally have the best coverage outcome. The coverage pathway for brand Adderall almost always runs through prior authorization, step therapy documentation, or a medical necessity exception.

ADHD is among the most common neurodevelopmental conditions in the United States. The CDC's 2019 National Survey of Children's Health reported that 9.8% of children ages 3 to 17 had ever received an ADHD diagnosis [3]. Among adults, a 2006 American Journal of Psychiatry study (N=3,199) estimated a 4.4% 12-month prevalence of DSM-IV ADHD [4]. The high population burden means stimulant formulary policies have wide financial impact on SelectHealth members.

Prior Authorization for Adderall: What SelectHealth Requires

Prior authorization (PA) is the process by which a prescriber submits clinical documentation to SelectHealth justifying medical necessity before the plan will cover a drug at the formulary tier rate. For Adderall, SelectHealth's PA criteria typically include:

A confirmed ADHD diagnosis supported by standardized rating scales (Conners, Vanderbilt, ADHD-RS-IV, or equivalent). A trial of at least one lower-tier stimulant, often generic methylphenidate or generic amphetamine salts IR, documented as ineffective or not tolerated. An age-appropriate assessment, since PA criteria for pediatric patients (under 6 years) and adults may differ. Documentation that the prescriber is licensed and actively treating the patient for ADHD, not a one-time prescriber.

The prior authorization request is submitted by the prescribing clinician, not the patient. Once submitted, SelectHealth is required under Utah state law and federal ACA rules to respond to standard PA requests within 72 hours and to urgent PA requests within 24 hours.

If SelectHealth approves the PA, brand Adderall may be covered at the applicable tier copay for an authorization period, usually 12 months, after which re-authorization is required. The American Academy of Pediatrics 2019 Clinical Practice Guideline for ADHD states: "For elementary school-age children (6 to 11 years of age), the primary care clinician should prescribe FDA-approved medications for ADHD and may prescribe behavior therapy as a first-line treatment." [5] That guideline's recognition of medication as a primary treatment supports the clinical case made during prior authorization.

Step Therapy: What It Means for Adderall Coverage

Step therapy (also called fail-first) requires that a patient try a lower-cost or preferred drug before the plan will cover a more expensive one. For brand Adderall specifically, SelectHealth step therapy commonly requires documented use of generic amphetamine salts IR or generic methylphenidate products first.

Methylphenidate (Ritalin, Concerta, and generic equivalents) is a distinct chemical entity from amphetamine. A 2018 Cochrane review of 260 randomized controlled trials covering 23,000 participants found that both amphetamine and methylphenidate improved ADHD symptoms versus placebo in children, with amphetamine compounds showing a marginally larger effect size in some outcomes [6]. That clinical difference is real, but most insurers treat the drug classes as therapeutically interchangeable for step therapy purposes.

Step therapy exceptions are available. Utah's Step Therapy Act (Utah Code Section 31A-22-647) requires that insurers grant a step therapy exception when the required first-step drug is contraindicated, has already been tried and failed, or would cause clinically significant harm. If a prescriber documents that a patient previously failed methylphenidate or generic amphetamine formulations, SelectHealth must evaluate that exception request within the standard PA timeline. Supplying pharmacy records, prior prescriber notes, or patient-reported adverse effects strengthens the exception submission.

How to Appeal a SelectHealth Adderall Denial

Denials happen. When SelectHealth denies a PA for Adderall or a step therapy exception, the member and prescriber have several options.

Internal Appeal. File an internal appeal within 180 days of the denial notice. Submit additional clinical documentation: office visit notes confirming diagnosis, records of prior medication trials, any specialist letters from a psychiatrist or neurologist, and relevant standardized assessment scores. SelectHealth must resolve standard internal appeals within 30 days and expedited appeals (for urgent clinical situations) within 72 hours under ACA Section 2719 requirements.

External Review. If the internal appeal is denied, members on fully-insured SelectHealth commercial plans have the right to external review through an independent review organization (IRO) accredited by URAC or NCQA. The external reviewer's decision is binding on SelectHealth for covered-benefit disputes.

State Insurance Commissioner. The Utah Insurance Department accepts complaints about coverage denials. Filing a complaint sometimes prompts plan-level review outside the standard appeal track.

Medicare Advantage Appeals. For SelectHealth Medicare Advantage members, the appeals chain follows CMS rules: Level 1 (plan redetermination, 60 days), Level 2 (Qualified Independent Contractor review, 60 days), Level 3 (Office of Medicare Hearings and Appeals, if the amount in controversy exceeds $180), Level 4 (Medicare Appeals Council), Level 5 (Federal District Court). The CMS Medicare Prescription Drug Benefit Manual Chapter 18 governs these timelines [7].

A study published in JAMA Internal Medicine (2021, N=43,427 denied claims) found that fewer than 1% of patients whose claims were denied filed an appeal, yet appeal overturn rates for those who did file reached 39% to 59% depending on the plan type [8]. Filing an appeal is worth the effort.

Covered Adderall Alternatives on SelectHealth Formularies

If brand Adderall remains unaffordable or uncovered after exhausting the PA and appeal process, several covered alternatives treat ADHD with established evidence.

Generic amphetamine salts IR/XR. The most direct substitute. FDA bioequivalence standards require these generics to deliver 80% to 125% of the brand's pharmacokinetic profile. Most SelectHealth plans cover these at Tier 1 or Tier 2.

Lisdexamfetamine (Vyvanse). A prodrug converted to d-amphetamine in the body. FDA-approved for ADHD in patients age 6 and older and for binge eating disorder. Vyvanse carries a lower potential for abuse than immediate-release amphetamine because absorption requires enzymatic conversion. It is typically Tier 3 on SelectHealth commercial plans and requires PA, but a 70 mg Vyvanse generic (lisdexamfetamine dimesylate) became available in 2023 following patent expiration, which may reduce cost-share on some SelectHealth formularies.

Methylphenidate ER (Concerta generics, Ritalin LA). Often Tier 1 or 2. The AHRQ's 2011 Comparative Effectiveness Review No. 44, covering 2,396 patients across 54 trials, found methylphenidate ER formulations reduced ADHD symptom scores significantly versus placebo [9]. Extended-release formulations reduce dosing frequency and may improve adherence.

Atomoxetine (Strattera, generic). A selective norepinephrine reuptake inhibitor. Not a stimulant. Not a Schedule II substance. FDA-approved for ADHD in adults and children age 6 and older. Useful when stimulant use is contraindicated (e.g., certain cardiac conditions, history of stimulant misuse). Generic atomoxetine became available in 2017 and sits on Tier 1 or 2 on most SelectHealth commercial plans.

Viloxazine ER (Qelbree). FDA-approved in 2021 for pediatric ADHD (ages 6 to 17) and in 2022 for adults. A selective norepinephrine reuptake inhibitor structurally distinct from atomoxetine. May be covered under specialty carve-out benefits depending on the SelectHealth plan.

Guanfacine ER (Intuniv, generic) and Clonidine ER (Kapvay, generic). Alpha-2 agonists used as adjuncts or monotherapy in pediatric ADHD. Both have generic versions on most Tier 1 formularies. The AAP 2019 guideline endorses these as adjunctive therapy when stimulants alone are insufficient [5].

Discussing these alternatives with a prescriber does not mean accepting inferior treatment. In clinical practice, the "best" ADHD medication is the one that controls symptoms, causes tolerable side effects, and fits the patient's daily schedule.

The Ongoing Amphetamine Shortage and Its Coverage Implications

In October 2022, the FDA declared a shortage of amphetamine mixed salts products, citing manufacturing capacity issues at major generic producers [10]. That shortage persisted through 2023 and into 2024, creating situations where covered generic amphetamine salts were unavailable at pharmacies even when the insurance benefit was intact.

The shortage created a secondary coverage problem: when a patient's covered generic was out of stock, switching to a different manufacturer's generic or to brand Adderall sometimes triggered a new PA requirement because the NDC (National Drug Code) changed. SelectHealth and other carriers issued temporary shortage-related exception policies in 2022 and 2023, allowing pharmacists to dispense available alternatives without a new PA. Members should confirm the current status of any active PA when switching manufacturers due to stock issues.

The FDA's drug shortage database remains the most current source for amphetamine availability status, updated weekly [10]. Prescribers can also call SelectHealth's pharmacy services line to confirm whether a specific NDC is covered under an existing authorization.

What to Tell Your Doctor to Strengthen a SelectHealth Adderall PA Request

The prescribing clinician drives the prior authorization process, but patients who understand what documentation is needed can accelerate approval.

Bring records of any previous ADHD medication trials, including the drug name, dose, duration of use, and reason for stopping. A written timeline showing you tried methylphenidate 18 mg to 54 mg for 8 weeks and experienced inadequate symptom control carries more weight than a verbal report. Standardized rating scale scores (ADHD-RS-IV, Adult ADHD Self-Report Scale) obtained before and after a previous trial are particularly useful.

Bring documentation of functional impairment. School records showing academic struggles, employer documentation of workplace difficulties, or neuropsychological testing results help establish that ADHD is producing real-world harm that warrants specific treatment.

If a specialist (psychiatrist, neuropsychologist, developmental pediatrician) has evaluated you, request a letter specifically addressing why brand Adderall or a specific amphetamine formulation is medically necessary for your case. SelectHealth PA reviewers give specialist opinions weight in complex cases.

The American Psychiatric Association's 2023 Practice Guideline for ADHD notes that "adequate pharmacotherapy involves matching the formulation and delivery mechanism to the patient's daily schedule, comorbid conditions, and prior medication response history." [11] That framing supports individualized prescribing arguments in PA submissions.

Cost Without Coverage: What to Expect

If prior authorization is denied and all appeal options are exhausted, brand Adderall remains available at cash pay, but pricing is substantial. A 30-count supply of brand Adderall 20 mg typically lists above $300 at retail pharmacies without insurance. Generic amphetamine salts 20 mg, 30-count, runs approximately $30 to $60 with GoodRx or similar discount programs, sometimes less than the Tier 2 copay on some SelectHealth plans.

Manufacturer savings programs: Teva Pharmaceuticals (a major generic producer) and Shire/Takeda (brand Vyvanse) have historically offered copay assistance cards for commercially insured patients. These cards are generally not usable for Medicare or Medicaid beneficiaries under federal anti-kickback rules. Patients with SelectHealth commercial plans may use these cards to reduce out-of-pocket cost on covered prescriptions.

The 340B Drug Pricing Program allows certain federally qualified health centers and disproportionate-share hospitals to acquire medications at reduced cost. Patients receiving care at a 340B-eligible Intermountain Health facility may access lower-cost dispensing through the facility pharmacy.

Checking Your Specific Plan Before Assuming Coverage

Coverage specifics vary by plan year and plan type. Three concrete steps every SelectHealth member should take before assuming Adderall is covered:

First, use the SelectHealth online drug search tool at selecthealth.org, entering "amphetamine" or "Adderall" with your plan name and current plan year. The tool shows tier placement, quantity limits, and whether PA is required.

Second, call SelectHealth Member Services at the number on the back of your insurance card and ask specifically: Is NDC [your pharmacy's specific NDC for the drug] covered under my plan? Is prior authorization required? What are the PA criteria?

Third, ask your prescribing clinician's office whether they have experience submitting PAs to SelectHealth for stimulants. Many practices with ADHD-focused providers have templates that match SelectHealth's current PA criteria, reducing approval time.

A 2020 analysis in Health Affairs (N=34.7 million pharmacy claims) found that prior authorization delays for ADHD medications averaged 5.3 days and resulted in a 29% rate of treatment abandonment when patients did not have clinical support navigating the PA process [12]. Having a clinician who manages the PA submission actively reduces that abandonment risk.